BOULDER, Colo., Dec. 20, 2017 (GLOBE NEWSWIRE) — Findings Published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrate that a test based on a protein signature associated with Patient outcome in metastatic melanoma can effectively predict survival in patients receiving PD-1 blocking antibodies. The test, developed with Biodesix’s proprietary Diagnostic Cortex® machine learning platform, is based on mass spectrometry analysis of patient serum. “Understanding the biology of immune-resistant patients is critical to providing those patients with optimal therapy,” said Dr. Jeffrey Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU-Langone, […]